Topics
Sector
Geography
Subject

Videos Library

Bio-similar, but different: Establishing (or defending) value through Multi-Criteria Decision Analytic (MCDA) modelling

Related topics: Pharmaceutical/Biotech, Europe, Market Access & HEOR, Biosimilars

This free video is available for registered users

Overview
  • How the complex characteristics of biologics (and biosimilars) contribute to perceived value to different stakeholders.
  • The salient issues facing Upstarts (marketers of biosimilars) and Defenders (marketers of “original” biologics) in communicating comparative worth to stakeholders.
  • How MCDA modelling methods can assist both groups in better defining and communicating value.
Speaker

Mason W. Russell
Vice President, Strategic Consulting (Life Sciences)
Truven, USA

Photo

Subscribe or unlock this video to download the presentation slides. If you already have an account, please log in.

REMINDER

This is the presenters’ personal opinion and does not necessarily represent true facts, the official views or policy of their organisation, nor the views of Evidence Life Science.

Sponsor